优化AAV包装条件制备AAV8/hFⅧ及其对血友病A小鼠的基因治疗研究
该研究通过比较不同细胞与质粒比例摸索AAV包装条件,发现20 cm培养皿转染20 μg质粒效率最高,并以此包装纯化AAV8/hFⅧ。以8×10(12) vg/kg尾静脉注射血友病A小鼠后,FⅧ活性维持治疗水平达12周。
要点
- 20 cm培养皿转染20 μg质粒为最佳AAV包装条件。
- AAV8/hFⅧ以8×10(12) vg/kg注射HA小鼠,FⅧ活性维持治疗水平12周。
- 优化包装条件制备的AAV8/hFⅧ在HA小鼠体内显示长期治疗效果。
核心结论
- 利用优化包装条件制备的AAV8/hFⅧ能在血友病A小鼠体内有效维持治疗水平的FⅧ活性达12周。
研究设计与样本
- 研究在HEK-293细胞中比较四种质粒转染条件以优化AAV包装,并包装纯化AAV8/hFⅧ。
- 纯化AAV8/hFⅧ以8×10(12) vg/kg经尾静脉注射血友病A小鼠,每两周行眼底出血并以aPTT测定FⅧ活性。
主要发现
- 20 cm培养皿转染20 μg质粒的条件在转染后24、48和72 h均达到最佳转染效果。
- 该条件包装的AAV2粗提液在16095细胞中感染率较高。
- HA小鼠注射AAV8/hFⅧ后12周FⅧ活性仍维持在治疗水平。
关键数值与推荐
- 最佳包装条件为20 cm培养皿转染20 μg质粒。
- AAV8/hFⅧ注射剂量为8×10(12) vg/kg。
- FⅧ活性维持治疗水平至注射后12周。
临床怎么用
- 为血友病A基因治疗中AAV8/hFⅧ的包装条件优化和体内长期疗效评估提供实验依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the effects of adeno-associated virus (AAV) carrying hFⅧ by serotype 8 (AAV8/hFⅧ) on hemophilia A (HA) mice by gene therapy strategy. Methods: pAAV-CB-EGFP, pH22 (serotype 2) and pfΔ6 (adenovirus helper) were used to package AAV into HEK-293 cells in different conditions (ratios of cells to plasmids). The efficiency of transfection and infection were evaluated using immunofluorescence microscope to seek an optimized package condition. pAAV-TTR-hFⅧ, pH 28 (serotype 8) and pfΔ6 were applied to package AAV8/hFⅧ in HEK-293 cells using the optimized package condition. The purified AAV8/hFⅧ were intravenously injected into HA mice and the effects of gene therapy were estimated. Results: The efficiency of package was evaluated according to the amount and intensity of enhanced green fluorescent protein (EGFP) under immunofluorescence microscope. Four package conditions including 10 cm-dish to transfect 10 μg plasmids, 20 cm-dish to 20 μg, 30 μg and 40 μg plasmids were employed, and the condition of 20 cm-dish to transfect 20 μg plasmids reached the highest transfection efficiency at 24 h, 48 h and 72 h after transfection. The small scale AAV-EGFP was packaged using the optimized condition and an AAV crude extract was harvested by a freeze-thaw method. HEK-293 and 16095 cells were infected by the AAV crude extract, and the preferential infection efficiency was recognized in 16095 cells under immunofluorescence microscope. Then, AAV8/hFⅧ was packaged and purified based on the optimized transfection condition, and the high purity of AAV8/hFⅧ was detected by Western blot. Fractions of AAV8/hFⅧ at the dose of 8×10(12) vg/kg were injected into HA mice through tail vein, an eye-bleeding was performed at every two weeks, and the activity of FⅧ was measured by aPTT assay. Results showed that the activity of FⅧ maintained at the therapeutic level and lasted up to 12 weeks after injection. Conclusion: The purified AAV8/hFⅧ based on the optimized package condition could play a role in HA mice gene therapy, and the long-term therapeutic effects of AAV8/hFⅧ were observed in vivo. 目的: 评价携带人凝血因子FⅧ(hFⅧ)的重组腺相关病毒(AAV)血清型8(AAV8/hFⅧ)病毒治疗血友病A(HA)小鼠效果。 方法: 应用pAAV-CB-EGFP,pH22(AAV2血清型)和pfΔ6(腺病毒辅助质粒)摸索在HEK-293细胞中AAV的包装条件,pH22、pfΔ6及pAAV-CB-EGFP质粒按照1∶1∶1的比例进行转染,免疫荧光显微镜观察四个条件(包括10 cm培养皿转10 μg质粒,20 cm培养皿分别转20、30和40 μg质粒)的病毒包装效果。应用最佳包装条件在HEK-293细胞中包装AAV2-EGFP,通过冻融法获得AAV2粗提液,感染HEK-293细胞和16095细胞,应用荧光显微镜观察包装效果。应用最佳转染条件将pAAV-TTR-hFⅧ、pH28、pfΔ6按1∶1∶1的比例转染HEK-293细胞获得AAV8/hFⅧ,两轮的氯化铯梯度离心法纯化病毒,以8×10(12) vg/kg剂量经尾静脉注射HA小鼠进行基因治疗,活化部分凝血活酶时间(APTT)测定分析FⅧ的活性。 结果: 20 cm培养皿转染20 μg质粒的条件能够在24、48和72 h都达到最佳的转染效果,且该条件包装的AAV2粗提液在16095细胞中具有较高的感染率。HA小鼠体内AAV8/hFⅧ能够在注射后12周仍有维持在治疗水平的FⅧ活性。 结论: 利用优化包装条件制备的AAV8/hFⅧ能够在HA小鼠体内有效维持治疗水平的FⅧ活性达12周。.
引用
- Mao JH, Shen Y, Wang Q, et al. [Optimized AAV package and experimental application of recombinant AAV8/hFⅧ for gene therapy on hemophilia A mice]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32023752. doi:10.3760/cma.j.issn.0253-2727.2020.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。